drugset / Trial / NCT00302341
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).
Timeline
- Start
- 2006-05
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pafuramidine | Small molecule | 100 mg | Oral |
| Comparator | trimethoprim-sulfamethoxazole | Unknown | 15 mg/kg | Oral |